Basic Fenofibrate Information

• INN (International Nonproprietary Name): Fenofibrate
• Brand names available in United Kingdom: Lipantil, Fenofibrate Accord
• ATC Code: C10AB05
• Forms & dosages: Capsules, Tablets (100mg, 145mg, 160mg, 200mg, 267mg)
• Manufacturers in United Kingdom: Accord, Sanofi
• Registration status in United Kingdom: Approved by the MHRA
• OTC / Rx classification: Prescription-only medication (Rx)

Latest Research Highlights

Recent clinical studies from 2022 to 2025 have reinforced the efficacy of fenofibrate in managing cholesterol and triglyceride levels. Notably, research from top UK and EU institutions has shed light on fenofibrate's positive impact on cardiovascular health. In one significant study, fenofibrate demonstrated substantial reductions in both LDL and triglyceride levels, offering hope for patients struggling with dyslipidaemia. New findings indicate that fenofibrate may contribute not only to managing lipid profiles but also to reducing cardiovascular events, showcasing a broader therapeutic benefit for high-risk patients. The following table summarises key clinical outcomes and safety data from recent trials, highlighting both the benefits and potential risks associated with fenofibrate therapy:

Study	Outcome	Lipid Profile Improvement	Associated Risks
Study 1	20% reduction in LDL	Significant triglyceride reduction	Minor gastrointestinal disturbances
Study 2	25% decrease in cardiovascular events	Improvement in HDL levels	Possible muscle pain

The insights from these studies affirm fenofibrate's role in cholesterol management, particularly for patients experiencing elevated triglyceride levels and those at risk for cardiovascular disease. The ongoing research continues to advocate for fenofibrate as a vital component in the broader spectrum of lipid-modifying agents.

Clinical Effectiveness in the UK

In the UK, the NHS has reported positive treatment outcomes for patients using fenofibrate. Many individuals with hyperlipidaemia and mixed dyslipidaemia have noted significant improvements in their conditions after starting fenofibrate therapy. Patient feedback reveals a trend towards improved lipid markers, indicating enhanced overall health outcomes. However, challenges remain. Some patients experience side effects such as gastrointestinal discomfort or muscle pain, which can affect adherence to treatment. According to qualitative data collected from platforms like Patient.info, the nuanced experiences of patients reflect the complexity of managing lipid disorders: - **Improvements in Health**: Many report feeling more energetic and confident after treatment. - **Adherence Issues**: A notable portion of patients express difficulty in consistently taking medication due to side effects. - **Education Importance**: There is a strong emphasis on the need for comprehensive information on managing expectations regarding therapy. Overall, while fenofibrate is proving effective for many, ongoing patient education and support are crucial for maximising treatment benefits.

Indications & Expanded Uses

Fenofibrate is primarily indicated for conditions such as hypercholesterolemia, mixed dyslipidaemia, and severe hypertriglyceridemia, all of which are recognised by the MHRA. Beyond these approved uses, fenofibrate has seen exploration for off-label applications within NHS and private settings. For instance, some clinicians are opting to prescribe fenofibrate for patients exhibiting mixed lipid disorders that do not fall neatly into standard categories. The advantages of this broader application can be significant, with particular focus on dual therapy in patients already on statins. However, prescribers must weigh potential risks, including side effects and the need for careful monitoring. This expanded view on fenofibrate's role in managing lipid disorders reinforces its place as a vital tool within therapeutic arsenal.

Composition & Brand Landscape

Fenofibrate consists of active ingredients specifically designed to aid in lipid modification. Its chemical structure marks it as part of the fibrate class, functioning primarily to reduce triglyceride levels and increase 'good' cholesterol (HDL). In the UK market, fenofibrate is available under several brand names, including Lipantil and Fenofibrate Accord. The key dosages and forms available are: | Brand Name | Dosage Form | Common Strengths | |----------------------------|------------------|---------------------| | Lipantil | Capsules | 200mg, 160mg | | Fenofibrate Accord | Tablets | 200mg, 160mg | This diversity in offerings caters to different patient needs and preferences, making fenofibrate accessible in various formulations tailored for effective lipid management.

Contraindications & Special Precautions

When considering fenofibrate as a treatment option, it's crucial to be aware of contraindications and special precautions. Absolute contraindications include severe hepatic and renal impairment, gallbladder disorders, and known hypersensitivity to fenofibrate. On the other hand, relative contraindications necessitate careful monitoring. These include situations involving mild to moderate kidney disease or a history of muscle-related disorders, particularly in the elderly or those co-treated with statins. Patients should be advised of lifestyle considerations during treatment, particularly with regard to driving and alcohol consumption while on fenofibrate. Addressing these factors ensures safer therapy and improves adherence, ultimately supporting positive health outcomes for patients.

Dosage Guidelines

When it comes to fenofibrate dosage guidelines, the NHS has specific recommendations for various clinical conditions. For patients with hypercholesterolemia, standard dosages are typically 160mg or 200mg daily, taken with food to enhance absorption. In cases of hypertriglyceridemia and mixed dyslipidemia, the same dosage range applies, allowing for flexibility depending on the exact preparation used.

Adjustments are crucial for certain populations:

• Elderly patients: Generally dosed like adults, but renal function should be monitored closely.
• Patients with renal impairment: Starting doses should be lower—typically 54mg or 67mg daily—and fenofibrate is not recommended at creatinine clearance rates below 30 mL/min.
• Liver impairment: Treatment is contraindicated in those with significant hepatic dysfunction.

It's vital that patients adhere to the prescribed dosing protocols to achieve the best therapeutic outcomes. Regular monitoring of lipid levels and renal function ensures a safe and effective treatment course while aiming for lipid control.

Interactions Overview

Food and drink interactions can play a role in the efficacy of fenofibrate, notably the effects of alcohol, tea, or coffee, which may alter absorption or bioavailability. Patients should limit or avoid alcohol consumption, as it can increase the risk of side effects.

From a medication perspective, the MHRA Yellow Card system highlights the importance of avoiding potential drug interactions. Particularly with other lipid-lowering medications, such as statins, the risk of myopathy or rhabdomyolysis can significantly increase. Patient counselling is crucial to prevent these adverse events and ensure safe use of fenofibrate.

Cultural Perceptions & Patient Habits

Insights gathered from NHS patient forums and platforms like Mumsnet reveal a range of cultural perceptions surrounding fenofibrate. Patients often express mixed feelings about the effectiveness and necessity of the medication. Some express trust in their pharmacists for guidance on its use, while others rely increasingly on NHS 111 for quick advice. This dynamic trust influences how patients adhere to treatment plans, impacting overall treatment adherence.

Furthermore, cultural attitudes towards medications can lead to differing levels of acceptance and willingness to engage with prescribed treatments. The outcome of these factors can significantly influence patient health outcomes and the effectiveness of fenofibrate therapy. Engaging with these dialogues is essential for healthcare providers to enhance understanding and adherence.

Availability & Pricing Patterns

Fenofibrate is available at major pharmacies in the UK, including Boots, LloydsPharmacy, and Superdrug. Pricing varies between NHS prescriptions and private purchases, often leading to confusion for patients. For instance, NHS prescriptions typically offer lower costs compared to out-of-pocket expenses for the same medication.

Regional variations across England, Wales, Scotland, and Northern Ireland also play a role in availability and pricing. Patients should be informed about accessing fenofibrate through NHS prescriptions versus the potential higher costs in private settings, empowering them to navigate their medication options more effectively.

Comparable Medicines and Preferences

When considering lipid management, fenofibrate isn't alone in the field. Competitor medications such as Gemfibrozil, Bezafibrate, and statins also come into play. Each medication has its own strengths, side effects, and patient preferences, influencing the decision-making process for treatment.

Here's a simplified comparison:

• Gemfibrozil: Effective but can cause gastrointestinal side effects.
• Bezafibrate: Similar to fenofibrate but may have less efficacy in triglyceride management.
• Statins: Generally effective for cholesterol, but may have risks of muscle pain and interactions with fenofibrate.

This checklist helps clinicians make informed prescribing decisions. Patient preferences based on past experiences should always be considered to tailor treatment to individual needs, ensuring better compliance and results in lipid management.

FAQ Section on Fenofibrate

Patients often have questions about fenofibrate, a medication primarily used for managing lipid levels. Here are some common queries.

How often should fenofibrate be taken?

Typically, fenofibrate is prescribed to be taken once daily, with or without food, depending on the formulation. It's essential to follow the specific guidelines given by the healthcare provider.

What side effects should be monitored?

Common side effects include mild nausea, headaches, and abdominal pain. More serious effects can involve muscle pain and liver enzyme changes, thus patients need to report unusual symptoms to their doctor.

Why are lifestyle changes important?

While fenofibrate can help lower cholesterol and triglyceride levels, it's only part of the treatment. Changes such as a healthy diet, regular exercise, and weight management complement the medication and improve overall cardiovascular health.

Can fenofibrate be used with other medications?

Fenofibrate may interact with other drugs, especially statins, and caution is required to avoid complications such as myopathy. Always consult a pharmacist or healthcare provider before starting new medications.

What should I do if I miss a dose?

If a dose is missed, take it as soon as remembered. However, if it's close to the next scheduled dose, skip the missed dose and continue with the usual routine. Never double the dose.

Guidelines for Proper Use of Fenofibrate

Utilising fenofibrate correctly is vital for its effectiveness. Here are best practices as recommended by pharmacists.

• Adhere to prescribed dosages: Always take the exact dose your healthcare provider recommends. Avoid changing the dosage without consultation.
• Regular health check-ups: Schedule consistent appointments for lipid level monitoring and assess any side effects. This helps ensure the therapy is working as intended.
• Utilise NHS patient advice portals: These resources provide valuable information and support for patients on fenofibrate.
• Engage in counselling sessions: Pharmacists offer counselling that can clarify usage instructions, address concerns, and provide support throughout the treatment journey.
• Be mindful of lifestyle recommendations: Following a balanced diet and engaging in regular exercise amplifies the benefits of fenofibrate and helps manage lipid levels effectively.

Patients may have unique circumstances that could influence treatment. Therefore, open communication with healthcare providers ensures that any potential issues are addressed timely. Whether it’s understanding the importance of regular medication adherence or following specific lifestyle modifications, maintaining a proactive approach to health management is critical.

City	Region	Delivery time
London	Greater London	5–7 days
Birmingham	West Midlands	5–7 days
Manchester	Greater Manchester	5–7 days
Glasgow	Scotland	5–7 days
Leeds	West Yorkshire	5–7 days
Bristol	South West England	5–7 days
Sheffield	South Yorkshire	5–7 days
Cardiff	Wales	5–7 days
Edinburgh	Scotland	5–7 days
Newcastle	Tyne and Wear	5–7 days
Nottingham	East Midlands	5–9 days
Southampton	Hampshire	5–9 days
Brighton	East Sussex	5–9 days
Coventry	West Midlands	5–9 days
York	North Yorkshire	5–9 days